Regulatory Bayer wins MHRA approval for Kerendia in heart failure PharmaTimesNew authorisation offers additional option for patients with lvef 40%RegulatoryCardiovascularRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) PharmaTimes New authorisation offers additional option for patients with lvef 40% RegulatoryCardiovascularRead full story Post navigation Previous: Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsNext: FDA hands another rejection to Replimune’s melanoma therapy Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026